The sNDA for empagliflozin (Jardiance) to reduce the risk of cardiovascular death and hospitalization for heart failure and slow kidney function decline in adults with chronic heart failure with ...

Results for EMPEROR-Reduced have been highly anticipated, as they are expected to set off a new round of competition in the drug class, which was first developed to treat type 2 diabetes.

Credit: Getty Images. The approval was based on data from the phase 3 EMPEROR-Reduced trial. The Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) to reduce the risk of ...

Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...

Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published in The Lancet RAHWAY, N.J., ...

Please provide your email address to receive an email when new articles are posted on . Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population. Pooled ...

NEW ORLEANS — Treatment with the SGLT2 inhibitor dapagliflozin reduced HF hospitalizations in patients with a broad range of left ventricular ejection fraction and may provide even greater benefit ...

to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction FARXIGA is not recommended for patients ...

"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...

The appraisal committee considered evidence submitted by Boehringer Ingelheim, a review of this submission by the evidence review group (ERG) and responses from stakeholders. See the committee papers ...